Published in Cancer Weekly, September 20th, 2005
In the United States, CTI plans to submit a New Drug Application (NDA) and seek approval for Xyotax as first-line monotherapy for women with advanced non-small cell lung cancer (NSCLC) who have poor performance status (PS2).
The filing in Europe will also seek use as monotherapy in first-line PS2 patients with NSCLC, but is not expected to be limited to women; however, additional input on the statistical interpretation of non-inferiority will be needed from the scientific committee of the European Medicines Agency...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.